Treatment of Non-Severe COVID-19 Outpatients With Xagrotin, Phase 3

• Status: Not yet recruiting
• Trial end date: 2022-07-07
• Target enrollment: 0
• Participant gender: All

Summary

This is an interventional, multi-center, randomized study. Adults with confirmed covid-19 disease not more than 10 days before enrollment date will be recruited (n=1000). Patients in same condition who get treated with standard of care will be randomly assigned to the control group (n=1000), and patients in same condition who get treated with standard of care will be randomly assigned to the placebo group (n=1000). The investigators analyze the effect of Xagrotin, and also investigate impact of different characteristics for instance gender, age, duration of disease, smoking habits and concomitant diseases on the outcome.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Biomad AS

Criteria

Inclusion Criteria:

• Age 18 or higher

• Newly diagnosed (no longer than 10 days)

• PCR or clinically confirmed Covid-19

Exclusion Criteria:

• Coronavirus patients admitted to medical centers for hospitalization and receive medical treatment and necessary care in medical centers